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Edited by Lukas HuberAbstract FGF-2 is a proangiogenic growth factor secreted by
unconventional means. It is unknown why FGF-2 takes an ER/
Golgi-independent secretory route. We ﬁnd that secretion of
FGF-2 via the ER/Golgi system causes post-translational modi-
ﬁcations that prevent binding to heparan sulfate proteoglycans
(HSPGs), an interaction that is critically important for both
FGF-2 storage and signal transduction. This loss of function is
due to artiﬁcial O-glycosylation mainly resulting in the addition
of glycosaminoglycan chains of the chrondroitin sulfate type.
Our ﬁndings suggest that the unconventional mechanism of
FGF-2 export is an ancient pathway of protein secretion that,
in the course of evolution, has been kept due to the inability of
the classical secretory pathway to export FGF-2 in a functional
form.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Unconventional secretory proteins are deﬁned by the ability
to exit cells by mechanisms that do not depend on the endo-
plasmic reticulum (ER) and the Golgi apparatus [1–4]. Export
of FGF-2 has been shown to be mediated by direct transloca-
tion across plasma membranes in an ATP-independent manner
[5]. From these ﬁndings, it has been concluded that FGF-2
membrane translocation is a diﬀusion-controlled process that
might be facilitated by a classical transporter or by alternative
means [6]. Directional net transport of FGF-2 into the extra-
cellular space depends on FGF-2 recruitment by phosphatidyl-
inositol-4,5-bisphosphate at the inner leaﬂet of plasma
membranes and a molecular trapping mechanism based on cell
surface HSPGs [7,6,8]. These data are consistent with observa-
tions indicating that FGF-2 remains folded during transport
across plasma membranes [9].
Here we addressed the question of why FGF-2 is not se-
creted by the ER/Golgi-dependent secretory pathway. Using
GFP fusion proteins, we systematically compared the extracel-*Corresponding author.
E-mail address: walter.nickel@bzh.uni-heidelberg.de (W. Nickel).
0014-5793/$34.00  2008 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2008.05.042lular populations of the normal form of FGF-2, a signal-pep-
tide-containing form of FGF-2 (SP-FGF-2) as well as FGF-4,
a relative of FGF-2 that naturally contains a signal peptide
and is secreted via the ER/Golgi-dependent secretory pathway.
We found that the secreted population of the normal form of
FGF-2 is quantitatively retained on cell surfaces where it is
bound to HSPGs. By contrast, both SP-FGF-2 and FGF-4
were released in substantial amounts into the medium of cells.
As opposed to FGF-2, the secreted forms of both SP-FGF-2
and FGF-4 were glycosylated. While the vast majority of se-
creted SP-FGF-2 contained glycosaminoglycan chains of the
chondroitin sulfate type, FGF-4 was characterized by N-linked
sugars. The consequences of these modiﬁcations were quite dif-
ferent as we found that SP-FGF-2 neither binds to heparin nor
to HSPGs. By contrast, N-glycosylated FGF-4 eﬃciently
bound to both heparin and HSPGs. The combined data pre-
sented in this study suggest that FGF-2 secreted by the ER/
Golgi-dependent secretory pathway can neither be stored
and protected by HSPGs within the extracellular matrix and
on cell surfaces nor can it be functional in terms of HSPG-
dependent signal transmission as part of ternary complexes
involving FGF-2, HSPGs and FGF receptors.2. Results
2.1. Addition of a signal peptide to FGF-2 results in secretion of
post-translationally modiﬁed forms that are not retained by
cell surface HSPGs
Using a well-characterized model system based on CHO
cells and GFP fusion proteins, we have characterized the extra-
cellular populations of FGF-2, SP-FGF-2 and FGF-4 with re-
gard to export eﬃciency, post-translational modiﬁcations as
well as binding to heparin and cell surface HSPGs. We found
FGF-2 on cell surfaces, however, when FGF-2 was expressed
in CHO mutant cells that do not make HSPGs (CHO-745;
[10]), cell surface staining was almost completely abolished
(Fig. 1, panel A, note log scale of y-axis). These ﬁndings are
consistent with our earlier observations demonstrating that
CHO-745 cells cannot secrete FGF-2 [7]. The majority of
FGF-2 could be eluted from the surfaces of CHO wild-type
cells by heparin (Fig. 2, panel B). Similar results were obtained
for FGF-4, however, in case of CHO-745 cells, the cell surface
signal was only reduced to about 20% as compared to CHO
wild-type cells (Fig. 1, panel A, note log scale of y-axis). This
eﬀect was even more pronounced for SP-FGF-2-GFP asblished by Elsevier B.V. All rights reserved.
Fig. 1. Rerouting to the ER/Golgi-dependent secretory pathway results in the secretion of aberrant forms of FGF-2. (A) FACS-based quantitation
of cell surface-associated material of FGF-2-GFP, SP-FGF-2-GFP and FGF-4-GFP (green bars = GFP expression level; red bars = cell surface
staining). All measurements were normalized by setting the levels of FGF-2-GFP to 100%. (B) Heparin-mediated elution of FGF-2-GFP, SP-FGF-2-
GFP and FGF-4-GFP from cell surfaces. (C) Biochemical analysis of FGF-2-GFP, SP-FGF-2-GFP and FGF-4-GFP in cell lysates and cellular
supernatants. (D) Subcellular localization of FGF-2-GFP, SP-FGF-2-GFP and FGF-4-GFP in CHO wild-type and CHO-745 cells. For further
details see text.
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faces of CHO wild-type and CHO-745 cells, respectively. Con-
sistently, elution of both SP-FGF-GFP and FGF-4-GFP fromthe cell surfaces of CHO-745 cells could not be observed (Fig.
1, panel B). These data establish that both SP-FGF-2-GFP
and FGF-4-GFP can bind to sites on cell surfaces that are
Fig. 2. The high molecular weight forms of SP-FGF-2 ([) originate
from the addition of glycosaminoglycan chains of the chondroitin
sulfate type. (A) SP-FGF-2-GFP expressed in CHO wild-type cells.
(B), SP-FGF-2-GFP expressed in CHO-745 mutant cells. (C) SP-FGF-
2-GFP expressed in CHO-677 mutant cells. (D) FGF-4-GFP expressed
in CHO wild-type cells. (E) FGF-4-GFP expressed in CHO-745 cells.
(F) FGF-4-GFP expressed in CHO-677 cells. Lane 1: cell lysate. Lanes
2–10: Immunoprecipitated material from cellular supernatants. Lanes
2, 5, and 8: Mock-treated samples. Lanes 3, 6, and 9: Samples treated
with the enzyme indicated. Lanes 4, 7, and 10: Samples treated with
heat-inactivated enzymes. For further details see text.
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were taken as a ﬁrst hint that, as opposed to FGF-2 and
FGF-4, SP-FGF-2 could not bind to HSPGs.
As shown by confocal microscopy, addition of a signal pep-
tide to FGF-2 (to generate SP-FGF-2) indeed caused its rero-
uting to the ER/Golgi system as indicated by the lack of diﬀuse
cytoplasmic and nuclear localization. Instead, like FGF-4,
intracellular SP-FGF-2 was localized in perinuclear structures
likely to represent the ER/Golgi system (Fig. 1, panel D). As
opposed to FGF-2 but similar to FGF-4, SP-FGF-2 was not
only found on cell surfaces (Fig. 1, panel A) but rather sub-
stantial amounts of SP-FGF-2 were also secreted into the med-ium of both CHO wild-type and CHO-745 cells (Fig. 1,
panel C). As compared to the intracellular population, SP-
FGF-2 being secreted into the medium of cells was apparently
modiﬁed. A broad range of high molecular weight forms were
observed that were clearly distinct from unmodiﬁed FGF-2
(Fig. 1, panel C). In contrast to SP-FGF-2, the secreted popu-
lation of FGF-4 found in cellular supernatants was repre-
sented by only one major species (Fig. 1, panel C).2.2. Rerouting of FGF-2 to the classical secretory pathway
results in the addition of glycosaminoglycans of the
chrondroitin sulfate type
In order to characterize the apparent post-translational
modiﬁcations of secreted SP-FGF-2, we conducted enzymatic
digestions combined with the expression of SP-FGF-2 in CHO
wild-type and various mutant cell lines deﬁcient in glycosami-
noglycan synthesis (Fig. 2). We compared digestion with hep-
arinase III (to target heparan sulfates; [11]), PNGase F (to
target N-glycosylation; [12]) and chrondroitinase ABC (to tar-
get chondroitin sulfate; [13]) as indicated. When secreted SP-
FGF-2 was derived from CHO wild-type cells (Fig. 2, panel
A), the high molecular weight forms ([) were neither aﬀected
by heparinase III nor by PNGase F, however, treatment with
chrondroitinase ABC resulted in its complete digestion (lane
9). Consistently, as shown in panel B of Fig. 2, the high molec-
ular weight forms of SP-FGF-2 were absent from the cell cul-
ture supernatants of CHO mutant cells that cannot add any
glycosaminoglycan chains to target proteins (CHO-745; [10]).
By contrast, CHO mutant cells that cannot transfer heparan
sulfates, however, are able to modify target proteins with gly-
cosaminoglycans of the chrondroitin sulfate type (CHO-677;
[14,15]) did secrete the high molecular weight forms of FGF-
2-GFP which, in turn, were digestible with chrondroitinase
ABC (Fig. 2, panel C, lane 9).
In the experiments shown in Fig. 2 (panels A–C), a small frac-
tion of secreted SP-FGF-2 was detected that was still running
slower (t; Fig. 2, lanes 2–10) than the material found in cell ly-
sates (i; Fig. 2, lane 1). This modiﬁed form of SP-FGF-2 was nei-
ther aﬀected by heparinase III, PNGaseF nor by chrondroitinase
ABC treatment. It was secreted frombothCHOwild-type aswell
as from CHO-745 and 677 mutant cells. These ﬁndings suggest
that, in addition to receiving glycosaminoglycans of the chron-
droitin sulfate type, SP-FGF-2 becomes O-glycosylated at an-
other site resulting in the low molecular weight form (t).
As opposed to SP-FGF-2, secreted FGF-4 was represented
by just one discrete form (r; Fig. 2, panels D–F, lanes 2–5
and 7–10) that was running more slowly compared to the
material found in cell lysates (i; Fig. 2, panels D–F, lane 1).
As shown in Fig. 2, the secreted form of FGF-4 was unaﬀected
in the presence of both heparinase III and chrondroitinase
ABC. By contrast, this population could be digested with
PNGaseF suggesting that secreted FGF-4 derived from CHO
cells is N-glycosylated which is in line with previous reports
[16]. Consistently, the modiﬁed form of FGF-4 was secreted
from all CHO cell lines being tested.2.3. SP-FGF-2 fails to bind both heparin and heparan sulfate
proteoglycans
In a third set of experiments we tested whether secreted SP-
FGF-2 binds to cell surface HSPGs and heparin. To systemat-
ically compare FGF-2, SP-FGF-2 and FGF-4 we developed a
Fig. 3. SP-FGF-2 is deﬁcient in binding to cell surface HSPGs. FGF-2-GFP, SP-FGF-2-GFP, and FGF-4-GFP, respectively, were expressed in
CHO wild-type and CHO-745 cells and co-cultivated with the various CHO acceptor cells as indicated. Cell-surface-associated material from FGF-2-
GFP-expressing CHO wild-type cells cultivated as a homogenous cell population was used to normalize all data. Red bars indicate cell-surface-
associated material of cells expressing the reporter molecules noted above. Orange bars indicate the amounts of cell-surface-associated material on
CHO acceptor cells. For further details see text.
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cell surfaces (Fig. 3). This was achieved by co-cultivation of
CHO acceptor cells that do not express any of the FGFs being
studied. As a control we also used HSPG-deﬁcient CHO-745
cells as acceptors. Both the material on the surface of the
FGF-expressing cells (red bars) and the material on the surface
of the CHO acceptor cells (orange bars) were quantiﬁed by
ﬂow cytometry. The signals were normalized by quantiﬁcation
of the cell surface signal of FGF-2-expressing CHO wild-type
cells grown as a homogenous culture. When FGF-2 expressing
CHO wild-type cells were mixed with CHO wild-type acceptor
cells eﬃcient transfer was observed. In case CHO-745 cells
were used, transfer of FGF-2 was almost completely abolished
demonstrating that transfer to CHO wild-type cells was depen-
dent on HSPGs. As reported previously [7], the FGF-2
secretion deﬁciency of CHO-745 cells could be overcome by
co-cultivation with CHO wild-type cells exposing HSPGs on
their cell surfaces. Strikingly, as shown in Fig. 3, expression
of SP-FGF-2 in both CHO wild-type and CHO-745 cells did
not result in transfer to CHO acceptor cells irrespective of
whether the latter were CHO wild-type or CHO 745 mutant
cells. By contrast, secretion of FGF-4 from both CHO wild-
type and CHO-745 cells did result in eﬃcient transfer to
CHO wild-type cells, however, there was no signal when
CHO-745 cells were used as acceptors. These data demonstrate
that FGF-2 secretion via the classical ER/Golgi-dependent
pathway results in the failure of the secreted molecule to bind
to cell surface HSPGs. By contrast, both non-classical secre-
tion of FGF-2 and secretion of FGF-4 via the classical secre-
tory pathway results in secreted molecules that are functional
with regard to binding to cell surface HSPGs.
These data were conﬁrmed by experiments investigating the
binding of SP-FGF-2 and FGF-4 to heparin in vitro (Fig. 4).
Similar to recombinant FGF-2-GFP and a non-tagged form of
FGF-2 that were used as positive controls (Fig. 4, panels E and
F, respectively, lane 2), secreted FGF-4 derived from both
CHO wild-type and CHO-745 mutants cells could be shown
to eﬃciently bind to heparin (Fig. 4, panels C and D, lane 2).
By contrast, irrespective of whether secreted from CHO wild-
type or from CHO 745 mutant cells (Fig. 4, panels A and B,
lane 2), binding of SP-FGF-2-GFP to heparin could not be ob-
served. These experiments also demonstrated that the GFP tag
in all fusion proteins used throughout this study does not aﬀect
binding eﬃciency to heparin. From the combined data shownin Figs. 3 and 4 we conclude that rerouting of FGF-2 to the
ER/Golgi-dependent secretory pathway results in secreted
molecules that cannot bind to heparan sulfate proteoglycans.3. Discussion
We have addressed the question as to why FGF-2 takes an
alternative secretory route that does not rely on the classical
ER/Golgi-dependent pathway. Consistent with earlier studies
[17,18], we demonstrate that FGF-2 is eﬃciently secreted when
artiﬁcially targeted to the lumen of the ER (SP-FGF-2). These
ﬁndings suggest that a general incompatibility of FGF-2 with
transport along the classical secretory pathway does not exist.
We found, however, that the vast majority of the secreted pop-
ulation of SP-FGF-2 is post-translationally modiﬁed by O-
linked glycosaminoglycans and that these forms of SP-FGF-
2 fail to bind to cell surface HSPGs, an interaction that is crit-
ically important for both FGF-2 storage in the extracellular
space and FGF-2-mediated signal transduction.
Based on the expression in various CHO mutant cell lines
and combined with enzymatic digestions we demonstrate that
the secreted population of SP-FGF-2 is O-glycosylated. In par-
ticular, in cellular supernatants, high molecular weight forms
of SP-FGF-2 accumulate that are generated by the addition
of glycosaminoglycan chains. These aberrant forms of FGF-
2 are not secreted from CHO-745 mutant cells [10], a cell line
with a general block in glycosminoglycan synthesis. By con-
trast, in case of CHO-677 cells [14,15], a cell line that cannot
produce heparan sulfates, however, is capable of synthesizing
glycosaminoglycans of the chrondroitin sulfate type, the high
molecular weight forms of SP-FGF-2 are present in cellular
supernatants. Consistently, enzymatic digestion with chondro-
itinase ABC resulted in the degradation of these modiﬁed
forms of SP-FGF-2. The combined data establish that, when
FGF-2 is targeted to the ER/Golgi system via an artiﬁcial sig-
nal peptide, it becomes modiﬁed with glycosaminoglycan
chains of the chondroitin sulfate type and is secreted eﬃciently.
In the second part of this work we found that, as opposed to
the normal 18 kDa form of FGF-2, SP-FGF-2 modiﬁed with
glycosaminoglycans looses its ability to bind to both HSPGs
and heparin. This was shown by co-cultivation experiments
using living cells and by in vitro studies analyzing binding
Fig. 4. SP-FGF-2 is deﬁcient in binding to heparin in vitro. Cell
culture supernatants either derived from CHO wild-type (panels A and
C) or CHO-745 mutant cells (panels B and D) expressing SP-FGF-2-
GFP (panels A and B) and FGF-4-GFP (panels C and D),
respectively, were incubated with immobilized heparin. As positive
controls, recombinant FGF-2-GFP and a non-tagged form of
recombinant FGF-2 were used (panels E and F, respectively). Lane
1: Input (50% following immnuoprecipitation). Lane 2: Bound fraction
(50%). Lane 3: Flow-through fraction (50% following immnuoprecip-
itation).
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eﬃcient binding of FGF-2 secreted by the normal alternative
pathway, modiﬁed SP-FGF-2 completely failed to bind to
both cell surface HSPGs and heparin. In all of these studies,
we systematically compared FGF-2 and SP-FGF-2 with
FGF-4, a close relative of FGF-2 that naturally contains a sig-
nal peptide and is secreted via the ER/Golgi-dependent path-
way. Interestingly, even though structurally related [19],
FGF-4 does not receive O-linked glycosaminoglycans within
the lumen of the ER/Golgi system. Rather, we show that the
secreted population of FGF-4 is N-glycosylated, a modiﬁca-
tion that is compatible with binding to both cell surface
HSPGs and heparin.
A major role of the interaction between FGF-2 and HSPGs
on cell surfaces and in the extracellular matrix is storage andprotection against degradation and denaturation of extracellu-
lar FGF-2 [20–22]. In the light of the current data, it becomes
evident that this physiological function of HSPGs is not com-
patible with the secretion of FGF-2 based on the ER/Golgi-
dependent pathway. Additionally, FGF-2-mediated signal
transduction in most cases depends on ternary complexes of
FGF-2, HSPGs and high aﬃnity FGF receptors [23]. Our data
are therefore consistent with previous studies demonstrating
that FGF-2 secreted from the ER/Golgi-dependent pathway
has no or only little mitogenic activity [17]. Therefore, as op-
posed to what has been concluded in a recent study [24], it re-
mains questionable whether signal-peptide-containing forms
of FGF-2 could be relevant as a therapeutic tool to deliver
large amounts of FGF-2 in a functional form. In conclusion,
our data suggest that the unconventional secretory pathway
of FGF-2 represents an ancient mechanism of protein secre-
tion that, in the course of evolution, was not replaced by the
more complex, ER/Golgi-dependent pathway to export
FGF-2. Our ﬁndings suggest that this is due to the inability
of the ER/Golgi-dependent pathway to secrete FGF-2 in a
physiologically active form.4. Materials and methods
4.1. Reagents and cell lines
A signal-peptide-containing form of FGF-2 (SP-FGF-2) was gener-
ated by transplanting the natural FGF-4 signal peptide
(MSGPGTAAVALLPAVLLALLAPWAGRGGAAAPTAP) to the
N-terminus of the 18 kDa form of FGF-2. Stable CHO wild-type,
CHO-745 [10] and CHO-677 [14,15] mutant cell lines, respectively,
were generated by retroviral transduction as described before [25].
Antibodies used for ﬂow cytometry and biochemical experiments were
directed against GFP (monoclonal, Clontech), FGF-2 (monoclonal,
clone FB-8, Sigma), and FGF-4 (monoclonal, clone 19805.11, Abcam).4.2. Quantiﬁcation of FGF-2 secretion based on ﬂow cytometry
Stable cell lines expressing FGF-2, SP-FGF-2, and FGF-4, respec-
tively, in a doxicycline-dependent manner were used to quantify overall
expression levels (GFP ﬂuorescence) and cell-surface-exposed material
by antibody staining as described before [25,7]. Where indicated cells
were treated with heparin (125 lg/ml) to quantify cell surface-associ-
ated material that was bound to HSPGs.4.3. Biochemical analysis of FGF-2 secretion
Cells were grown in six-well plates to about 80% conﬂuency. To ana-
lyze the appearance of FGF-2, SP-FGF-2, and FGF-4, respectively, we
immunoprecipitated them from cellular supernatants followed by
SDS–PAGE (Invitrogen NuPage, 4–12% Bis–Tris gel using MOPS
SDS running buﬀer) and Western blot analysis using monoclonal anti-
bodies directed against FGF-2 and FGF-4, respectively. Fifty percent
of the immunoprecipitates were compared to about 1% of the corre-
sponding cell lysates.
4.4. Confocal microscopy
CHO cells were grown on glass coverslips (MatTek Corp. Ashland,
USA), processed for live cell imaging and viewed with a Zeiss LSM 510
confocal microscope.
4.5. Analysis of post-translational modiﬁcations by enzymatic digestions
Cells were grown in six-well plates to about 80% conﬂuency. SP-
FGF-2 and FGF-4, respectively, were immunoprecipitated from the
cellular supernatants of the cell lines indicated and 50% of each immu-
noprecipitate were analyzed by SDS–PAGE (Invitrogen NuPage, 4-
12% Bis–Tris gel using MOPS SDS running buﬀer) and Western blot
analysis. Where indicated, immunoprecipitates were treated with hep-
arinase III (from Flavobacterium heparinum; Sigma H8891),
PNGase F (Peptide-N-glycosidase F; Sigma P7367) and
2392 S. Wegehingel et al. / FEBS Letters 582 (2008) 2387–2392chondroitinase ABC (Chondroitinase ABC from Proteus
vulgaris; Sigma C3667). As controls, immunoprecipitates were
mock-treated or incubated with heat-inactivated enzymes. In each
case, cell lysates (0.5%) were analyzed for comparison.
4.6. Quantiﬁcation of FGF-2 binding to cell surface HSPGs by co-
cultivation experiments
Binding of secreted FGF-2, SP-FGF-2, and FGF-4-GFP, respec-
tively, to cell surface HSPGs was measured by co-cultivation experi-
ments using various kinds of CHO acceptor cells as described
previously [7].
4.7. Analysis of FGF-2 binding to heparin in vitro
Cells were grown in six-well plates to about 80% conﬂuency. The cel-
lular supernatants of CHO wild-type and CHO-745 cells expressing
SP-FGF-2-GFP and FGF-4-GFP, respectively, were incubated with
heparin-coated beads (Heparin Sepharose 6 Fast Flow, GE
Healthcare). Bound and unbound material was separated and
50% of each fraction were analyzed by SDS–PAGE (12%) and Western
blot analysis. Input material was generated by direct immunoprecipita-
tion of SP-FGF-2-GFP and FGF-4-GFP from the corresponding cel-
lular supernatants. As a positive control, recombinant FGF-2-GFP
(0.6 lg) was used.References
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